Surface Oncology Inc (NASDAQ:SURF) traded up 38.2% during mid-day trading on Wednesday . The stock traded as high as $2.26 and last traded at $1.99, 685,700 shares were traded during trading. An increase of 941% from the average session volume of 65,840 shares. The stock had previously closed at $1.44.
SURF has been the subject of a number of recent analyst reports. Cowen restated a “buy” rating on shares of Surface Oncology in a research report on Wednesday, November 13th. Zacks Investment Research cut Surface Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, ValuEngine raised Surface Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
The company has a debt-to-equity ratio of 0.28, a current ratio of 7.34 and a quick ratio of 7.34. The company has a 50-day simple moving average of $1.49 and a 200-day simple moving average of $2.48. The stock has a market cap of $51.03 million, a PE ratio of -6.03 and a beta of 2.32.
A number of hedge funds have recently added to or reduced their stakes in SURF. EcoR1 Capital LLC increased its holdings in Surface Oncology by 2.2% in the second quarter. EcoR1 Capital LLC now owns 2,312,688 shares of the company’s stock valued at $6,522,000 after buying an additional 49,200 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Surface Oncology by 8.3% in the 2nd quarter. Acadian Asset Management LLC now owns 100,120 shares of the company’s stock worth $283,000 after acquiring an additional 7,640 shares during the period. Paloma Partners Management Co acquired a new stake in shares of Surface Oncology in the 2nd quarter worth approximately $119,000. Jane Street Group LLC acquired a new stake in shares of Surface Oncology in the 2nd quarter worth approximately $82,000. Finally, Tower Research Capital LLC TRC increased its stake in Surface Oncology by 323.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 25,497 shares of the company’s stock valued at $36,000 after purchasing an additional 19,482 shares in the last quarter. 56.56% of the stock is currently owned by hedge funds and other institutional investors.
Surface Oncology Company Profile (NASDAQ:SURF)
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27.
Read More: What is a capital gain?
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.